Why CoreWeave Stock Slipped This Week

CoreWeave (CRWV) stock experienced significant volatility and a 3.2% decline last week, reflecting mixed investor sentiment surrounding its proposed $9 billion acquisition of Core Scientific. The stock's performance was impacted by an ISS recommendation for Core Scientific shareholders to reject the offer, fueling fears of an increased bid, despite CEO Michael Intrator's subsequent assurance that CoreWeave would not raise its price. With Core Scientific's shareholder vote on October 30th widely expected to reject the deal, a non-approval could paradoxically serve as a near-term positive catalyst for CoreWeave, as a substantial portion of its shareholders view the acquisition as detrimental to the company's interests.

Analysis

CoreWeave (CRWV) stock declined 3.2% last week, underperforming the S&P 500 (+1.9%) and Nasdaq Composite (+2.3%), due to significant investor uncertainty surrounding its proposed $9 billion acquisition of Core Scientific. This volatility occurred despite CRWV's substantial year-to-date gain of 231% in 2025, highlighting the market's focus on the M&A transaction.

Sentiment deteriorated after investment firm ISS recommended on October 20 that Core Scientific shareholders reject the buyout, prompting sell-offs in CRWV on fears of an increased bid. CoreWeave CEO Michael Intrator's subsequent assurance that the company would not raise its offer failed to fully alleviate concerns, as shares continued to fluctuate, reflecting mixed shareholder views on the deal's strategic value.

The Core Scientific shareholder vote on October 30 is broadly expected to result in the rejection of CoreWeave's bid. This anticipated non-approval is paradoxically viewed by a significant portion of CoreWeave shareholders as a potential near-term positive catalyst, as it would remove a perceived strategic misstep and allow the company to refocus.

Key Decisions for Investors

• Monitor the Core Scientific shareholder vote on October 30 closely, as a rejection of the $9 billion buyout is widely expected and could serve as a near-term positive catalyst for CRWV stock.
• Evaluate CoreWeave's strategic direction and capital allocation post-acquisition decision, considering the company's strong 2025 year-to-date performance (+231%) independent of this specific M&A activity.
• Assess the underlying AI growth narrative for CoreWeave, as the current M&A-driven volatility may present an entry point if the Core Scientific deal is ultimately abandoned and the market refocuses on core business fundamentals.